Electric field therapy before brain tumor surgery shows promise in early trial

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patient is aged \>35 years (age range of more likely to suffer from an IDHwt World Health Organisation (WHO) grade 4 astrocytoma)\* * Patient is male or female. * Patient has a new radiological diagnosis of glioblastoma. * Patient has a performance status judged by WHO, Eastern Cooperative Oncology Group (ECOG) score = 0-1. * Patient has been reviewed by Neuro-oncology multidisciplinary team (MDT - neurosurgeon, clinical oncologist, radiologist and pathologist); MDT consensus that offering study entry is clinically appropriate and safe i.e. patient unlikely to come to harm (e.g. hydrocephalus) from delayed surgery and pre-operative Optune based on available clinical information and imaging. * PI has confirmed at the first clinic visit that study entry is clinically appropriate and safe (e.g. lack of severe and debilitating symptoms of raised intracranial pressure). * There is intention to treat the patient with surgical resection and postoperative adjuvant therapy as per current standard of care (40Gy/15 fr or 60Gy/30fr). * Patient has adequate haematological and biochemical parameters for surgery and contrast agent administration (full blood count and coagulation profile deemed acceptable by clinical team, eGFR \>30ml/min). * Patient has mental capacity to consent for treatment. * Patient is able and willing to give informed consent Criteria specific to the experimental arm: * Patient is able and willing to comply with study protocol requirements to continuously shave their head * Patient is able and willing to comply with study protocol requirements to wear Optune equipment for the required duration. Exclusion Criteria: * Patients with uncontrolled seizures. * Patients are due to undergo a planned biopsy procedure only. * Patients have a suspicion of other tumour on CT body scan or known malignancy except non-melanoma skin cancer, completely resected or prostate cancer (with Prostate Specific Antigen of less than or equal to 0.1 ng/ml) within the past three years. * Patients have contraindications to contrast-enhanced MRI scanning (e.g. claustrophobia, gadolinium allergy).